NEW YORK, NY / ACCESSWIRE / April 3, 2018 / U.S. equities fell sharply on Monday, weighed down by losses in the technology sector and global trade concerns. The Dow Jones Industrial Average decreased 1.90 percent to close at 23,644.19, while the S&P 500 Index shed 2.23 percent to close at 2,581.88. The Nasdaq Composite Index dropped 2.74 percent to close at 6,870.12.
"Today's weakness has everything to do with China's announced tariffs. Even though they were quite small, there's a fear that this could escalate. We don't know if this could be the end as far as retaliation goes, but it seems like the trade issue is escalating into bite and not just bark," said Hank Smith, chief investment officer at Haverford Trust Co.
RDI Initiates Coverage on:
Portola Pharmaceuticals, Inc.
Intrexon's stock moved 1.57% lower Monday, to close the day at $15.09. The stock recorded a trading volume of 1,379,091 shares, which was below its three months average volume of 1,883,467 shares. In the last year, Intrexon's shares have traded in a range of 10.26 - 26.99. The share price has gained 47.08% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $15.02 is greater than its 200-day moving average of $14.98. Shares of Intrexon have fallen roughly 6.22 percent in the past month and are up 30.99 percent year-to-date.
Access RDI's Intrexon Corporation Research Report at:
On Monday, shares of Portola Pharmaceuticals recorded a trading volume of 960,100 shares, which was below the three months average volume of 1,264,614 shares. The stock ended the day 4.50% lower at 31.19. The stock is currently trading 53.52% below its 52 week high with a 52 week trading range of 30.10 - 67.10. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $38.45 is below its 200-day moving average of $47.69. Shares of Portola Pharmaceuticals have fallen roughly 8.93 percent in the past month and are down 35.93 percent year-to-date.
Access RDI's Portola Pharmaceuticals, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.